1887

Journal of Medical Microbiology logo

Volume 68, Issue 5

Epidemiology and susceptibility profile to classic antifungals and over-the-counter products of clinical isolates from a Portuguese University Hospital: a prospective study Free

Abstract

Clinical epidemiological data about the distinct species remain scarce. The recurrence of -related skin diseases, despite long-term use of antifungals, raises concern about the hypothetical emergence of antifungal resistance. We aimed to assess the distribution of species among patients from a University Hospital with pityriasis versicolor, seborrheic dermatitis and healthy volunteers, and to evaluate the susceptibility profile to classic antifungals and over-the-counter compounds, searching for clinical associations.

The enrollment of volunteers was conducted at the Dermatology Department of a University Hospital over a 3 year period. culture isolates were identified to the species-level by sequencing. The drug susceptibility profile was assessed according to a broth microdilution assay, as recommended by the Clinical Laboratory Standards Institute.

A total of 86 isolates were recovered from 182 volunteers. was the most frequent isolated species. We found high MIC values and a wide MIC range in the case of tested azoles, and very low terbinafine MIC values against most isolates. Previous topical corticosteroid therapy was associated with a significant increase of MIC values of fluconazole and of terbinafine.

Conversely to other European studies, was the most common isolated species, which might be related to geographic reasons. The impact of previous topical corticotherapy upon the antifungal susceptibility profile was hereby demonstrated. susceptibility test results suggest that terbinafine might be a valid alternative for -related skin diseases nonresponsive to azoles.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antifungal susceptibility , Azoles , Malassezia , pityriasis versicolor , seborrheic dermatitis , terbinafine and topical corticotherapy
© 2019 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000966
2019-05-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/68/5/778.html?itemId=/content/journal/jmm/10.1099/jmm.0.000966&mimeType=html&fmt=ahah

References

  1. Velegraki A, Cafarchia C, Gaitanis G, Iatta R, Boekhout T. Malassezia infections in humans and animals: pathophysiology, detection, and treatment. PLoS Pathog 2015; 11:e1004523 [View Article]
     [Google Scholar]
  2. Guillot J, Guého E. The diversity of Malassezia yeasts confirmed by rRNA sequence and nuclear DNA comparisons. Antonie Van Leeuwenhoek 1995; 67:297–314 [View Article]
     [Google Scholar]
  3. Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol 2013; 31:455–463 [View Article]
     [Google Scholar]
  4. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004; 51:785–798 [View Article]
     [Google Scholar]
  5. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360:387–396 [View Article]
     [Google Scholar]
  6. Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ et al. Global skin disease morbidity and mortality: an update from the global burden of disease study 2013. JAMA Dermatol 2017; 153:406–412 [View Article]
     [Google Scholar]
  7. Bjerre RD, Bandier J, Skov L, Engstrand L, Johansen JD. The role of the skin microbiome in atopic dermatitis: a systematic review. Br J Dermatol 2017; 177:1272–1278 [View Article]
     [Google Scholar]
  8. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012; 25:106–141 [View Article]
     [Google Scholar]
  9. Pedrosa AF, Lisboa C, Rodrigues AG. Malassezia infections with systemic involvement: figures and facts. J Dermatol 2018; 45:1278–1282 [View Article]
     [Google Scholar]
  10. Iatta R, Figueredo LA, Montagna MT, Otranto D, Cafarchia C. In vitro antifungal susceptibility of Malassezia furfur from bloodstream infections. J Med Microbiol 2014; 63:1467–1473 [View Article]
     [Google Scholar]
  11. Crespo Erchiga V, Ojeda Martos AA, Vera Casaño A, Crespo Erchiga A, Sánchez Fajardo F. [Isolation and identification of Malassezia spp. In pytiriasis versicolor, seborrheic dermatitis and healthy skin.]. Rev Iberoam Micol 1999; 16:S16–21
     [Google Scholar]
  12. Aspiroz C, Moreno LA, Rezusta A, Rubio C. Differentiation of three biotypes of Malassezia species on human normal skin. correspondence with M. globosa, M. sympodialis and M. restricta . Mycopathologia 1999; 145:69–74 [View Article]
     [Google Scholar]
  13. Aspiroz C, Ara M, Varea M, Rezusta A, Rubio C. Isolation of Malassezia globosa and M. sympodialis from patients with pityriasis versicolor in Spain. Mycopathologia 2002; 154:111–117 [View Article]
     [Google Scholar]
  14. Gomez-Moyano E, Crespo-Erchiga V, Martínez-Pilar L, Godoy Diaz D, Martínez-García S et al. Do Malassezia species play a role in exacerbation of scalp psoriasis?. J Mycol Med 2014; 24:87–92 [View Article]
     [Google Scholar]
  15. Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm Venereol 2015; 95:12–19 [View Article]
     [Google Scholar]
  16. Rojas FD, Sosa Mde L, Fernández MS, Cattana ME, Córdoba SB et al. Antifungal susceptibility of Malassezia furfur, Malassezia sympodialis, and Malassezia globosa to azole drugs and amphotericin B evaluated using a broth microdilution method. Med Mycol 2014; 52:641–646 [View Article]
     [Google Scholar]
  17. Rojas FD, Córdoba SB, de Los Ángeles Sosa M, Zalazar LC, Fernández MS et al. Antifungal susceptibility testing of Malassezia yeast: comparison of two different methodologies. Mycoses 2017; 60:104–111 [View Article]
     [Google Scholar]
  18. Leong C, Buttafuoco A, Glatz M, Bosshard PP. Antifungal susceptibility testing of Malassezia spp. with an optimized colorimetric broth microdilution method. J Clin Microbiol 2017; 55:1883–1893 [View Article]
     [Google Scholar]
  19. Gupta AK, Kohli Y. Prevalence of Malassezia species on various body sites in clinically healthy subjects representing different age groups. Med Mycol 2004; 42:35–42 [View Article]
     [Google Scholar]
  20. Kaneko T, Makimura K, Abe M, Shiota R, Nakamura Y et al. Revised culture-based system for identification of Malassezia species. J Clin Microbiol 2007; 45:3737–3742 [View Article]
     [Google Scholar]
  21. Silva-Dias A, Miranda IM, Branco J, Cobrado L, Monteiro-Soares M et al. In vitro antifungal activity and in vivo antibiofilm activity of cerium nitrate against Candida species. J Antimicrob Chemother 2015; 70:1083–1093 [View Article]
     [Google Scholar]
  22. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009; 47:2392–2397 [View Article]
     [Google Scholar]
  23. Sugita T, Suto H, Unno T, Tsuboi R, Ogawa H et al. Molecular analysis of Malassezia microflora on the skin of atopic dermatitis patients and healthy subjects. J Clin Microbiol 2001; 39:3486–3490 [View Article]
     [Google Scholar]
  24. Gaitanis G, Velegraki A, Frangoulis E, Mitroussia A, Tsigonia A et al. Identification of Malassezia species from patient skin scales by PCR-RFLP. Clin Microbiol Infect 2002; 8:162–173 [View Article]
     [Google Scholar]
  25. Velegraki A, Alexopoulos EC, Kritikou S, Gaitanis G. Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest. J Clin Microbiol 2004; 42:3589–3593 [View Article]
     [Google Scholar]
  26. Grice EA, Dawson TL Jr. Host-microbe interactions: Malassezia and human skin. Curr Opin Microbiol 2017; 40:81–87 [View Article]
     [Google Scholar]
  27. Gupta AK, Kohli Y, Faergemann J, Summerbell RC. Epidemiology of Malassezia yeasts associated with pityriasis versicolor in Ontario, Canada. Med Mycol 2001; 39:199–206 [View Article]
     [Google Scholar]
  28. Lee YW, Byun HJ, Kim BJ, Kim DH, Lim YY et al. Distribution of Malassezia species on the Scalp in Korean seborrheic dermatitis patients. Ann Dermatol 2011; 23:156–161 [View Article]
     [Google Scholar]
  29. Gemmer CM, DeAngelis YM, Theelen B, Boekhout T, Dawson TL Jr. Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002; 40:3350–3357 [View Article]
     [Google Scholar]
  30. Sugita T, Takashima M, Kodama M, Tsuboi R, Nishikawa A. Description of a new yeast species, Malassezia japonica, and its detection in patients with atopic dermatitis and healthy subjects. J Clin Microbiol 2003; 41:4695–4699 [View Article]
     [Google Scholar]
  31. Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic Dermatitis, pityriasis versicolor and normal subjects. Med Mycol 2000; 38:337–341 [View Article]
     [Google Scholar]
  32. Raabe P, Mayser P, Weiss R. Demonstration of Malassezia furfur and M. sympodialis together with M. pachydermatis in veterinary specimens. Mycoses 1998; 41:493–500
     [Google Scholar]
  33. Honnavar P, Prasad GS, Ghosh A, Dogra S, Handa S et al. Malassezia arunalokei sp. nov., a novel yeast species isolated from seborrheic dermatitis patients and healthy individuals from India. J Clin Microbiol 2016; 54:1826–1834 [View Article]
     [Google Scholar]
  34. Pedrosa AF, Lisboa C, Faria-Ramos I, Silva RM, Miranda IM et al. Malassezia species retrieved from skin with pityriasis versicolor, seborrhoeic dermatitis and skin free of lesions: a comparison of two sampling methods. Br J Dermatol 2018; 179:526–527 [View Article]
     [Google Scholar]
  35. Faergemann J, Bergbrant IM, Dohsé M, Scott A, Westgate G. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144:549–556 [View Article]
     [Google Scholar]
  36. Kistowska M, Fenini G, Jankovic D, Feldmeyer L, Kerl K et al. Malassezia yeasts activate the NLRP3 inflammasome in antigen-presenting cells via Syk-kinase signalling. Exp Dermatol 2014; 23:884–889 [View Article]
     [Google Scholar]
  37. Carreira A, Ferreira JB, Pereira I, Ferreira J, Filipe P et al. Blad-containing oligomer: a novel fungicide used in crop protection as an alternative treatment for tinea pedis and tinea versicolor. J Med Microbiol 2018; 67:198–207 [View Article]
     [Google Scholar]
  38. Cafarchia C, Iatta R, Immediato D, Puttilli MR, Otranto D. Azole susceptibility of Malassezia pachydermatis and Malassezia furfur and tentative epidemiological cut-off values. Med Mycol 2015; 53:743–748 [View Article]
     [Google Scholar]
  39. Gupta AK, Foley KA. Antifungal treatment for pityriasis versicolor. J Fungi 2015; 1:13–29 [View Article]
     [Google Scholar]
  40. Faergemann J. Treatment of seborrhoeic dermatitis with oral terbinafine?. Lancet 2001; 358:170 [View Article]
     [Google Scholar]
  41. Youn HJ, Kim SY, Park M, Jung WH, Lee YW et al. Efficacy and safety of cream containing Climbazole/Piroctone Olamine for facial seborrheic dermatitis: a single-center, open-label Split-Face clinical study. Ann Dermatol 2016; 28:733–739 [View Article]
     [Google Scholar]
  42. Sepaskhah M, Sadat MS, Pakshir K, Bagheri Z. Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: a single blind, randomised clinical trial. Mycoses 2017; 60:338–342 [View Article]
     [Google Scholar]
  43. Sugita T, Tajima M, Ito T, Saito M, Tsuboi R et al. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 2005; 43:2824–2829 [View Article]
     [Google Scholar]
  44. Cobrado L, Silva-Dias A, Azevedo MM, Pina-Vaz C, Rodrigues AG. In vivo antibiofilm effect of cerium, chitosan and hamamelitannin against usual agents of catheter-related bloodstream infections. J Antimicrob Chemother 2013; 68:126–130 [View Article]
     [Google Scholar]
  45. Palmeira-de-Oliveira A, Ribeiro MP, Palmeira-de-Oliveira R, Gaspar C, Costa-de-Oliveira S et al. Anti-Candida activity of a chitosan hydrogel: mechanism of action and cytotoxicity profile. Gynecol Obstet Invest 2010; 70:322–327 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000966
Loading
Epidemiology and susceptibility profile to classic antifungals and over-the-counter products of Malassezia clinical isolates from a Portuguese University Hospital: a prospective study
J. Med. Microbiol. 68, 778 (2019); https://doi.org/10.1099/jmm.0.000966
/content/journal/jmm/10.1099/jmm.0.000966
/content/journal/jmm/10.1099/jmm.0.000966
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error